Motif Bio PLC FDA QIDP Designation (8174T)
July 22 2015 - 11:32AM
UK Regulatory
TIDMMTFB TIDMAMP
RNS Number : 8174T
Motif Bio PLC
22 July 2015
22 July 2015
Motif Bio plc
("Motif" or the "Company")
FDA QIDP Designation for Motif's Lead Antibiotic Candidate
Iclaprim for ABSSSI
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that the U.S. Food & Drug Administration (FDA) has designated
iclaprim, a broad-spectrum antibiotic designed to be effective
against multi-drug resistant bacteria, as a Qualified Infectious
Diseases Product (QIDP) for acute bacterial skin and skin structure
infections (ABSSSI).
The Company requested QIDP designation for iclaprim for two
serious and life threatening infections, hospital acquired
bacterial pneumonia (HABP) and ABSSSI. QIDP designation has already
been confirmed for HABP.
QIDP designation, provided under the Generating Antibiotic
Incentives Now Act (GAIN Act), makes iclaprim eligible for certain
incentives, including priority review and fast track designation.
With QIDP designation, iclaprim is now eligible for an additional
five-year extension of Hatch-Waxman exclusivity, for a total of 10
years of market exclusivity, starting from the date of NDA
approval.
Graham Lumsden, CEO of Motif Bio plc, said:
"QIDP designation for iclaprim has now been confirmed for the
two serious and life threatening infections that we applied for.
This is an important value driver for iclaprim and another positive
development for Motif and our investors. We believe that iclaprim
is the first and only dihydrofolate reductase inhibitor to receive
the QIDP designation."
Enquiries
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
Robert Bertoldi (Chief Financial
Officer)
www.motifbio.com
Zeus Capital Limited (Nominated +44 (0) 207
Advisor and Broker) 533 7727
Phil Walker / John Treacy
Dominic Wilson
Northland Capital Partners Limited +44 (0) 20
(Broker) 7382 1100
Patrick Claridge/David Hignell
John Howes/Mark Treharne (Broking)
Plumtree Capital Limited (Financial
Advisor) +44 (0) 207
Stephen Austin 183 2493
+49 (0) 89
MC Services AG (Public Relations) 210 2280
Raimund Gabriel +44 (0) 207
Shaun Brown 148 5998
Yellow Jersey PR Limited (Investor
Relations)
Dominic Barretto +44 (0) 7768
Fiona Walker 537 739
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which
specialises in developing novel antibiotics designed to be
effective against serious and life-threatening infections caused by
multi-drug resistant bacteria. The Company has a lead antibiotic
candidate, iclaprim, in clinical development and MTF-001, a
preclinical stage programme to design a best-in-class dihydrofolate
reductase inhibitor (DHFRi).
Iclaprim is being developed for the treatment of the most common
and serious bacterial infections such as acute bacterial skin and
skin structure infections (ABSSSI) and hospital acquired bacterial
pneumonia (HABP), including those caused by resistant strains such
as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP
(multi-drug resistant Streptococcus pneumoniae) that have become
prevalent in patients in both the community and hospital
settings.
This information is provided by RNS
The company news service from the London Stock Exchange
END
STASEAFIEFISEEW
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2023 to Apr 2024